Exercise of Option Year SPE2D217D0060P00006
ID: SPE2D217D0060Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES (6515)

Original Source

https://sam.gov/opp/599bf13b103e49739fe9cc68d2590112/view
Timeline
    Description

    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is exercising the option for the Hydrochlorothiazide National Contract. Hydrochlorothiazide is a medication used to treat high blood pressure and fluid retention. This procurement is for the supply of Hydrochlorothiazide, which is a medical and surgical instrument, equipment, and supply. For more information, please contact Denise Taubman at denise.taubman@dla.mil or 2157376877.

    Point(s) of Contact
    Denise Taubman
    (215) 737-6877
    denise.taubman@dla.mil
    Lifecycle
    Title
    Type
    EXERCISE OF OPTION HYDROCHLOROTHIAZIDE NATIONAL CONTRACT
    Currently viewing
    Special Notice
    Similar Opportunities
    Telmisartan Tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting proposals for the procurement of Telmisartan Tablets, a pharmaceutical product, to be delivered over multiple contract years. This solicitation, identified as SPE2D2-24-R-0015, requires compliance with various federal regulations, including the submission of a Subcontracting Plan for large businesses and adherence to Federal Acquisition Regulation (FAR) clauses concerning ethics and subcontracting practices. Telmisartan is crucial for managing hypertension and ensuring a reliable pharmaceutical supply is vital for military personnel's health. Interested vendors should submit their electronic proposals via the Defense Logistics Agency Internet Bid Board System (DIBBS) and can contact Courtney Hunter-Stangler at 215-737-6845 or via email at Courtney.Hunter-Stangler@dla.mil for further information.
    Valsartan
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    65--HYDROXYZINE HYDROCH
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA Troop Support), is seeking quotes for the procurement of Hydroxyzine Hydrochloride, specifically National Stock Number (NSN) 6505005799717, with a quantity of 50 units to be delivered to the 0703 CS BN CO A Distribution. This solicitation is a Total Small Business Set-Aside, emphasizing the importance of supporting small businesses in the pharmaceutical preparation manufacturing sector. Hydroxyzine is a critical medication used for its antihistamine properties, making this procurement vital for military medical needs. Interested vendors must submit their quotes electronically, as hard copies will not be provided, and any inquiries should be directed to the buyer via email at DibbsBSM@dla.mil.
    Bicalutamide 50MG tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is issuing a solicitation for a national requirements contract for Bicalutamide 50MG tablets, available in bottle counts of 30 and 500. The procurement aims to establish a reliable supply source for these pharmaceutical items, which are critical for various Department of Defense and other federal health programs, including the Department of Veterans Affairs and the Indian Health Service. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base and four one-year options, with proposals due by January 24, 2025. Interested parties can reach out to Keith Ryales at keith.ryales@dla.mil or 215-737-9199 for further inquiries and are encouraged to monitor the DLA Bid Board System and SAM.gov for updates on the solicitation.
    Doxycycline Hyclate Solicitation
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of Doxycycline Hyclate tablets under solicitation number SPE2D2-25-R-0004. The procurement aims to secure pharmaceutical products in various quantities and packaging configurations, with a focus on compliance with federal regulations and quality control measures. Doxycycline Hyclate is a critical antibiotic used in various medical applications, making this procurement essential for military and healthcare operations. Interested contractors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by February 5, 2025, at 3:00 PM EST, and can contact Courtney Hunter-Stangler or Jason C. Wray for further information.
    Doxycycline Hyclate
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    MODIFICATION TO ENALAPRIL NATIONAL CONTRACT
    Dept Of Defense
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking a modification to the ENALAPRIL NATIONAL CONTRACT. This modification aims to incorporate additional clauses into the existing contract. The ENALAPRIL NATIONAL CONTRACT is typically used for the procurement of enalapril, a medication used to treat high blood pressure and heart failure. The modification will ensure that the contract includes all necessary terms and conditions for the procurement of enalapril. For more information, please contact Denise Taubman at DENISE.TAUBMAN@DLA.MIL or 215-737-8677.
    Fluconazole - SPE2D221-D-0125-P00012 - Final Option Notice
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA Troop Support), has issued a special notice regarding the contract modification for Fluconazole under contract number SPE2D221-D-0125-P00012. This modification announces the exercise of the final option for the procurement of this pharmaceutical product, which is critical for various medical applications within military healthcare. Interested parties can reach out to the primary contact, Courtney Hunter-Stangler, at Courtney.Hunter-Stangler@dla.mil or by phone at 215-737-6845, or to the secondary contact, Jason Wray, at jason.wray@dla.mil or 215-737-0614, for further details regarding this opportunity.
    Finasteride Tablets
    Dept Of Defense
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Finasteride Tablets. Finasteride Tablets are typically used for the treatment of male pattern hair loss and benign prostatic hyperplasia. This procurement is for the incorporation of new clauses into an existing contract.
    Lansoprazole Capsules
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Lansoprazole capsules, specifically 30MG in 100 count bottles. This procurement aims to establish a national supply source for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons, ensuring a reliable supply of this essential pharmaceutical item. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, with the solicitation expected to be posted in April 2024. Interested parties should direct inquiries to Jeremy Brown at jeremy.brown@dla.mil or 215-737-6031, and are encouraged to set up automated notifications for updates on the solicitation through the DLA Bid Board System and Sam.Gov.